Polio prevention: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 16: Line 16:


Because of the risk of developing [[paralytic]] poliomyelitis with the OPV, developed countries only use the IPV form of the vaccine.<ref name=MMWR>{{cite web | title = Poliomyelitis Prevention in the United States | url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4905a1.htm }}</ref>
Because of the risk of developing [[paralytic]] poliomyelitis with the OPV, developed countries only use the IPV form of the vaccine.<ref name=MMWR>{{cite web | title = Poliomyelitis Prevention in the United States | url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4905a1.htm }}</ref>
===Inactivated Poliovirus Vaccine===
[[Vaccine]] containing the inactivated and more potent forms of the [[poliovirus|virus]].  IPV vaccine contains all 3 serotypes of the polivirus, and may be administered concomitantly with other routine vaccines or simply as trivalent IPV.  IPV should be administered in 4 doses, at the 2nd, 4th, and between the 6th and the 18th month of life, and than between the 4th and 6th year of life.<ref name=MMWR>{{cite web | title = Poliomyelitis Prevention in the United States | url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4905a1.htm }}</ref><ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>
The vaccine leads to the formation antibodies against the 3 serotypes of virus, after the 2nd dose in 99% of cases, and after the 3rd dose in 100% of cases.<ref name="pmid3020057">{{cite journal| author=Simoes EA, John TJ| title=The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. | journal=J Biol Stand | year= 1986 | volume= 14 | issue= 2 | pages= 127-31 | pmid=3020057 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3020057  }} </ref><ref name="pmid2843039">{{cite journal| author=McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R| title=Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. | journal=Am J Epidemiol | year= 1988 | volume= 128 | issue= 3 | pages= 615-28 | pmid=2843039 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2843039  }} </ref>  After the 3rd dose of the vaccine, [[antibody]] titers for [[serotype]]s 1 and 3 are higher in IPV, when compared to OPV, and similar for [[serotype]] 2.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>  Antibody titers may persist in circulation in some cases during 5 years.<ref name="pmid2881820">{{cite journal| author=Swartz TA, Roumiantzeff M, Peyron L, Stopler T, Drucker J, Epstein I et al.| title=Use of a combined DTP-polio vaccine in a reduced schedule. | journal=Dev Biol Stand | year= 1986 | volume= 65 | issue=  | pages= 159-66 | pmid=2881820 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2881820  }} </ref>  However the efficacy of the first two doses of IPV is thought to be inferior to the same two doses of OPV.<ref name="pmid2895828">{{cite journal| author=Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A et al.| title=Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. | journal=Lancet | year= 1988 | volume= 1 | issue= 8591 | pages= 897-9 | pmid=2895828 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2895828  }} </ref>
Children immunized with the IPV, when exposed to the live poliovirus, were more prone to shed greater amount of the virus in feces, and for a more extended period, when compared to children immunized with OPV.  This indicated a greater tendency to [[asymptomatic]] poliomyelitis and to transmission of the virus in these individuals.<ref name="pmid1845806">{{cite journal| author=Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH| title=Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. | journal=J Infect Dis | year= 1991 | volume= 163 | issue= 1 | pages= 1-6 | pmid=1845806 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1845806  }} </ref><ref name="pmid9203721">{{cite journal| author=Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA| title=Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. | journal=J Infect Dis | year= 1997 | volume= 175 Suppl 1 | issue=  | pages= S228-34 | pmid=9203721 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9203721  }} </ref>
===Oral Poliovirus Vaccine===
====Live-Attenuated Poliovirus Vaccine====
The live-attenuated poliovirus vaccine (OPV) is not available in the United States, however it is still used in other countries.  The intestinal immunity induced by the virus in the vaccine is thought to be identical to the one caused by the natural virus.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>  Commonly, after the first dose of OPV, children show the following [[seroconversion]] rates:<ref name="pmid7746690">{{cite journal| author=Cohen-Abbo A, Culley BS, Reed GW, Sannella EC, Mace RL, Robertson SE et al.| title=Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. | journal=Pediatr Infect Dis J | year= 1995 | volume= 14 | issue= 2 | pages= 100-6 | pmid=7746690 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7746690  }} </ref>
* Serotype 1 - 50%
* Serotype 2 - 85%
* Serotype 3 - 30%
On the second month after the third dose of OPV, the antibody prevalence to serotypes 1, 2 and 3 is > 96%.<ref name="pmid2843039">{{cite journal| author=McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R| title=Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. | journal=Am J Epidemiol | year= 1988 | volume= 128 | issue= 3 | pages= 615-28 | pmid=2843039 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2843039  }} </ref><ref name="pmid5442915">{{cite journal| author=Hardy GE, Hopkins CC, Linnemann CC, Hatch MH, Witte JJ, Chambers JC| title=Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules. | journal=Pediatrics | year= 1970 | volume= 45 | issue= 3 | pages= 444-8 | pmid=5442915 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5442915  }} </ref>  Vaccine immunization leads to maintenance of antibodies in circulation for up to 5 years.  Environmental re-exposure to the vaccine virus is thought to contribute to the persistence of antibodies in the population.<ref name="pmid206735">{{cite journal| author=Bass JW, Halstead SB, Fischer GW, Podgore JK, Wiebe RA| title=Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series. | journal=JAMA | year= 1978 | volume= 239 | issue= 21 | pages= 2252-5 | pmid=206735 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=206735  }} </ref><ref name="pmid6699021">{{cite journal| author=Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S et al.| title=The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. | journal=J Biol Stand | year= 1984 | volume= 12 | issue= 1 | pages= 1-10 | pmid=6699021 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6699021  }} </ref>  Following immunization with OPV, immunoglobulin A against the virus may be found in [[pharyngeal]] and [[duodenal]] secretions, between the 1st and 3rd weeks after administration, and may persist for more that 5 years.<ref name="pmid20617594">{{cite journal| author=Ogra PL, Karzon DT, Righthand F, MacGillivray M| title=Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. | journal=N Engl J Med | year= 1968 | volume= 279 | issue= 17 | pages= 893-900 | pmid=20617594 | doi=10.1056/NEJM196810242791701 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20617594  }} </ref><ref name="pmid6740074">{{cite journal| author=Ogra PL| title=Mucosal immune response to poliovirus vaccines in childhood. | journal=Rev Infect Dis | year= 1984 | volume= 6 Suppl 2 | issue=  | pages= S361-8 | pmid=6740074 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6740074  }} </ref>
After receiving the vaccine, nonimmune individuals shed the virus through pharyngeal secretions during 1 to 3 weeks, and through feces during 1 to 6 weeks. This shedding of the virus is considered positive, particularly in areas of poor vaccination, since it may contribute to the immunization of the community.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>
====Monovalent====   
The monovalent vaccine, the Sabin oral vaccine, introduced in 1961 consisted of 3 monovalent vaccines. These were later replaced by the trivalent OPV.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>
In 2005, in order to enhance the global efforts for the eradication of poliovirus in certain settings, the monovalent polivirus vaccine was re-introduced. The monovalent vaccine has higher immunogenicity for a certain serotype, when compared to the polyvalent kind, due to the absence of interference with other serotypes.  Additionally, the monovalent vaccine also provides a more focused approach in settings of single serotype outbreak.<ref name="pmid11462191">{{cite journal| author=Cáceres VM, Sutter RW| title=Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. | journal=Clin Infect Dis | year= 2001 | volume= 33 | issue= 4 | pages= 531-41 | pmid=11462191 | doi=10.1086/321905 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11462191  }} </ref><ref name="pmid18923170">{{cite journal| author=el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A et al.| title=Monovalent type 1 oral poliovirus vaccine in newborns. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 16 | pages= 1655-65 | pmid=18923170 | doi=10.1056/NEJMoa0800390 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18923170  }} </ref>


===Vaccination Guidelines===
===Vaccination Guidelines===
Line 51: Line 74:
|}
|}
====Guidelines in Polio-eradicated Regions====
====Guidelines in Polio-eradicated Regions====
===Inactivated Poliovirus Vaccine===
[[Vaccine]] containing the inactivated and more potent forms of the [[poliovirus|virus]].  IPV vaccine contains all 3 serotypes of the polivirus, and may be administered concomitantly with other routine vaccines or simply as trivalent IPV.  IPV should be administered in 4 doses, at the 2nd, 4th, and between the 6th and the 18th month of life, and than between the 4th and 6th year of life.<ref name=MMWR>{{cite web | title = Poliomyelitis Prevention in the United States | url = http://www.cdc.gov/mmwr/preview/mmwrhtml/rr4905a1.htm }}</ref><ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>
The vaccine leads to the formation antibodies against the 3 serotypes of virus, after the 2nd dose in 99% of cases, and after the 3rd dose in 100% of cases.<ref name="pmid3020057">{{cite journal| author=Simoes EA, John TJ| title=The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency. | journal=J Biol Stand | year= 1986 | volume= 14 | issue= 2 | pages= 127-31 | pmid=3020057 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3020057  }} </ref><ref name="pmid2843039">{{cite journal| author=McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R| title=Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. | journal=Am J Epidemiol | year= 1988 | volume= 128 | issue= 3 | pages= 615-28 | pmid=2843039 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2843039  }} </ref>  After the 3rd dose of the vaccine, [[antibody]] titers for [[serotype]]s 1 and 3 are higher in IPV, when compared to OPV, and similar for [[serotype]] 2.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>  Antibody titers may persist in circulation in some cases during 5 years.<ref name="pmid2881820">{{cite journal| author=Swartz TA, Roumiantzeff M, Peyron L, Stopler T, Drucker J, Epstein I et al.| title=Use of a combined DTP-polio vaccine in a reduced schedule. | journal=Dev Biol Stand | year= 1986 | volume= 65 | issue=  | pages= 159-66 | pmid=2881820 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2881820  }} </ref>  However the efficacy of the first two doses of IPV is thought to be inferior to the same two doses of OPV.<ref name="pmid2895828">{{cite journal| author=Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A et al.| title=Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine. | journal=Lancet | year= 1988 | volume= 1 | issue= 8591 | pages= 897-9 | pmid=2895828 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2895828  }} </ref>
Children immunized with the IPV, when exposed to the live poliovirus, were more prone to shed greater amount of the virus in feces, and for a more extended period, when compared to children immunized with OPV.  This indicated a greater tendency to [[asymptomatic]] poliomyelitis and to transmission of the virus in these individuals.<ref name="pmid1845806">{{cite journal| author=Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH| title=Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines. | journal=J Infect Dis | year= 1991 | volume= 163 | issue= 1 | pages= 1-6 | pmid=1845806 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1845806  }} </ref><ref name="pmid9203721">{{cite journal| author=Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA| title=Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. | journal=J Infect Dis | year= 1997 | volume= 175 Suppl 1 | issue=  | pages= S228-34 | pmid=9203721 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=9203721  }} </ref>
===Oral Poliovirus Vaccine===
====Live-Attenuated Poliovirus Vaccine====
The live-attenuated poliovirus vaccine (OPV) is not available in the United States, however it is still used in other countries.  The intestinal immunity induced by the virus in the vaccine is thought to be identical to the one caused by the natural virus.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>  Commonly, after the first dose of OPV, children show the following [[seroconversion]] rates:<ref name="pmid7746690">{{cite journal| author=Cohen-Abbo A, Culley BS, Reed GW, Sannella EC, Mace RL, Robertson SE et al.| title=Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. | journal=Pediatr Infect Dis J | year= 1995 | volume= 14 | issue= 2 | pages= 100-6 | pmid=7746690 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7746690  }} </ref>
* Serotype 1 - 50%
* Serotype 2 - 85%
* Serotype 3 - 30%
On the second month after the third dose of OPV, the antibody prevalence to serotypes 1, 2 and 3 is > 96%.<ref name="pmid2843039">{{cite journal| author=McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R| title=Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines. | journal=Am J Epidemiol | year= 1988 | volume= 128 | issue= 3 | pages= 615-28 | pmid=2843039 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2843039  }} </ref><ref name="pmid5442915">{{cite journal| author=Hardy GE, Hopkins CC, Linnemann CC, Hatch MH, Witte JJ, Chambers JC| title=Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules. | journal=Pediatrics | year= 1970 | volume= 45 | issue= 3 | pages= 444-8 | pmid=5442915 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=5442915  }} </ref>  Vaccine immunization leads to maintenance of antibodies in circulation for up to 5 years.  Environmental re-exposure to the vaccine virus is thought to contribute to the persistence of antibodies in the population.<ref name="pmid206735">{{cite journal| author=Bass JW, Halstead SB, Fischer GW, Podgore JK, Wiebe RA| title=Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series. | journal=JAMA | year= 1978 | volume= 239 | issue= 21 | pages= 2252-5 | pmid=206735 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=206735  }} </ref><ref name="pmid6699021">{{cite journal| author=Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S et al.| title=The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. | journal=J Biol Stand | year= 1984 | volume= 12 | issue= 1 | pages= 1-10 | pmid=6699021 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6699021  }} </ref>  Following immunization with OPV, immunoglobulin A against the virus may be found in [[pharyngeal]] and [[duodenal]] secretions, between the 1st and 3rd weeks after administration, and may persist for more that 5 years.<ref name="pmid20617594">{{cite journal| author=Ogra PL, Karzon DT, Righthand F, MacGillivray M| title=Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection. | journal=N Engl J Med | year= 1968 | volume= 279 | issue= 17 | pages= 893-900 | pmid=20617594 | doi=10.1056/NEJM196810242791701 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20617594  }} </ref><ref name="pmid6740074">{{cite journal| author=Ogra PL| title=Mucosal immune response to poliovirus vaccines in childhood. | journal=Rev Infect Dis | year= 1984 | volume= 6 Suppl 2 | issue=  | pages= S361-8 | pmid=6740074 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6740074  }} </ref>
After receiving the vaccine, nonimmune individuals shed the virus through pharyngeal secretions during 1 to 3 weeks, and through feces during 1 to 6 weeks. This shedding of the virus is considered positive, particularly in areas of poor vaccination, since it may contribute to the immunization of the community.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>
====Monovalent====   
The monovalent vaccine, the Sabin oral vaccine, introduced in 1961 consisted of 3 monovalent vaccines. These were later replaced by the trivalent OPV.<ref>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref>
In 2005, in order to enhance the global efforts for the eradication of poliovirus in certain settings, the monovalent polivirus vaccine was re-introduced. The monovalent vaccine has higher immunogenicity for a certain serotype, when compared to the polyvalent kind, due to the absence of interference with other serotypes.  Additionally, the monovalent vaccine also provides a more focused approach in settings of single serotype outbreak.<ref name="pmid11462191">{{cite journal| author=Cáceres VM, Sutter RW| title=Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. | journal=Clin Infect Dis | year= 2001 | volume= 33 | issue= 4 | pages= 531-41 | pmid=11462191 | doi=10.1086/321905 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11462191  }} </ref><ref name="pmid18923170">{{cite journal| author=el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A et al.| title=Monovalent type 1 oral poliovirus vaccine in newborns. | journal=N Engl J Med | year= 2008 | volume= 359 | issue= 16 | pages= 1655-65 | pmid=18923170 | doi=10.1056/NEJMoa0800390 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18923170  }} </ref>


==References==
==References==

Revision as of 16:30, 24 October 2016

Polio Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Poliovirus

Differentiating Polio from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Case Studies

Case #1

Polio prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Polio prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Polio prevention

CDC on Polio prevention

Polio prevention in the news

Blogs on Polio prevention

Directions to Hospitals Treating Polio

Risk calculators and risk factors for Polio prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]

Overview

Vaccination is the main form of prevention for poliomyelitis. Two types of the vaccine are available: an inactivated form (IPV), and a live-attenuated form (OPV). IPV is the current vaccine in the United States, contains all 3 serotypes of poliovirus and should be administered in 4 doses. The immune response to the vaccine produces antibodies against the 3 serotypes, which are present in 100% of the cases after the 3rd dose. The live-attenuated form may contain all serotypes of the virus or be given in the monovalent form. OPV immunization leads to maintenance of antibodies in circulation for up to 5 years. The monovalent form of OPV is useful to strengthen the immune response towards a specific serotype, or in cases of single serotype outbreak.

Prevention

Vaccination

As a result of the introduction of inactivated poliovirus vaccine (IPV) in the 1950s, followed by oral poliovirus vaccine (OPV) in the 1960s, poliomyelitis control has been achieved in numerous countries worldwide, including the entire Western Hemisphere.[1][2][3] Two forms of the vaccine are available, the Inactivated Poliovirus Vaccine (IPV) and the Live-Attenuated Poliovirus Vaccine (OPV). In 1955 the Salk IPV was introduced, leading to an important reduction of endemic and epidemic poliomyelitis. However, this form of the vaccine showed low potency, since 17% of the infants who had received the vaccine, developed paralytic poliomyelitis.[4] The OPV vaccine was introduced in 1962, as a monovalent vaccine, and the trivalent form was made available in 1964. This form of the vaccine was rapidly accepted in developing countries, due to:[5]

Because of the risk of developing paralytic poliomyelitis with the OPV, developed countries only use the IPV form of the vaccine.[1]

Inactivated Poliovirus Vaccine

Vaccine containing the inactivated and more potent forms of the virus. IPV vaccine contains all 3 serotypes of the polivirus, and may be administered concomitantly with other routine vaccines or simply as trivalent IPV. IPV should be administered in 4 doses, at the 2nd, 4th, and between the 6th and the 18th month of life, and than between the 4th and 6th year of life.[1][6]

The vaccine leads to the formation antibodies against the 3 serotypes of virus, after the 2nd dose in 99% of cases, and after the 3rd dose in 100% of cases.[7][8] After the 3rd dose of the vaccine, antibody titers for serotypes 1 and 3 are higher in IPV, when compared to OPV, and similar for serotype 2.[9] Antibody titers may persist in circulation in some cases during 5 years.[10] However the efficacy of the first two doses of IPV is thought to be inferior to the same two doses of OPV.[11]

Children immunized with the IPV, when exposed to the live poliovirus, were more prone to shed greater amount of the virus in feces, and for a more extended period, when compared to children immunized with OPV. This indicated a greater tendency to asymptomatic poliomyelitis and to transmission of the virus in these individuals.[12][13]

Oral Poliovirus Vaccine

Live-Attenuated Poliovirus Vaccine

The live-attenuated poliovirus vaccine (OPV) is not available in the United States, however it is still used in other countries. The intestinal immunity induced by the virus in the vaccine is thought to be identical to the one caused by the natural virus.[14] Commonly, after the first dose of OPV, children show the following seroconversion rates:[15]

  • Serotype 1 - 50%
  • Serotype 2 - 85%
  • Serotype 3 - 30%

On the second month after the third dose of OPV, the antibody prevalence to serotypes 1, 2 and 3 is > 96%.[8][16] Vaccine immunization leads to maintenance of antibodies in circulation for up to 5 years. Environmental re-exposure to the vaccine virus is thought to contribute to the persistence of antibodies in the population.[17][18] Following immunization with OPV, immunoglobulin A against the virus may be found in pharyngeal and duodenal secretions, between the 1st and 3rd weeks after administration, and may persist for more that 5 years.[19][20]

After receiving the vaccine, nonimmune individuals shed the virus through pharyngeal secretions during 1 to 3 weeks, and through feces during 1 to 6 weeks. This shedding of the virus is considered positive, particularly in areas of poor vaccination, since it may contribute to the immunization of the community.[21]

Monovalent

The monovalent vaccine, the Sabin oral vaccine, introduced in 1961 consisted of 3 monovalent vaccines. These were later replaced by the trivalent OPV.[22]

In 2005, in order to enhance the global efforts for the eradication of poliovirus in certain settings, the monovalent polivirus vaccine was re-introduced. The monovalent vaccine has higher immunogenicity for a certain serotype, when compared to the polyvalent kind, due to the absence of interference with other serotypes. Additionally, the monovalent vaccine also provides a more focused approach in settings of single serotype outbreak.[23][24]

Vaccination Guidelines

Guidelines in Endemic and High-Risk Regions

Vaccine Type Serotypes covered Number of Doses Vaccination Schedule in Endemic and High Risk Countries†
Birth 6 weeks 10 weeks 14 weeks
OPV *Monovalent (Serotype 2)
*Bivalent (Serotypes 1 & 3)‡
*Trivalent (Serotypes 1, 2, & 3) 		3 to 4 doses ✔ ✔ ✔ ✔
IPV *Serotype 1
*Serotype 2
*Serotype 3 		1 dose ✔
†Countries at high risk for importation and subsequent spread
‡Countries at high risk for importation and subsequent spread

Guidelines in Polio-eradicated Regions

References

  1. ↑ 1.0 1.1 1.2 "Poliomyelitis Prevention in the United States".
  2. ↑ Kim-Farley RJ, Bart KJ, Schonberger LB, Orenstein WA, Nkowane BM, Hinman AR; et al. (1984). "Poliomyelitis in the USA: virtual elimination of disease caused by wild virus". Lancet. 2 (8415): 1315–7. PMID 6150330.
  3. ↑ Nathanson N, Martin JR (1979). "The epidemiology of poliomyelitis: enigmas surrounding its appearance, epidemicity, and disappearance". Am J Epidemiol. 110 (6): 672–92. PMID 400274.
  4. ↑ Melnick JL (1978). "Advantages and disadvantages of killed and live poliomyelitis vaccines". Bull World Health Organ. 56 (1): 21–38. PMC 2395534. PMID 307445.
  5. ↑ Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.
  6. ↑ Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.
  7. ↑ Simoes EA, John TJ (1986). "The antibody response of seronegative infants to inactivated poliovirus vaccine of enhanced potency". J Biol Stand. 14 (2): 127–31. PMID 3020057.
  8. ↑ 8.0 8.1 McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R (1988). "Serologic response to oral polio vaccine and enhanced-potency inactivated polio vaccines". Am J Epidemiol. 128 (3): 615–28. PMID 2843039.
  9. ↑ Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.
  10. ↑ Swartz TA, Roumiantzeff M, Peyron L, Stopler T, Drucker J, Epstein I; et al. (1986). "Use of a combined DTP-polio vaccine in a reduced schedule". Dev Biol Stand. 65: 159–66. PMID 2881820.
  11. ↑ Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A; et al. (1988). "Clinical efficacy of a new, enhanced-potency, inactivated poliovirus vaccine". Lancet. 1 (8591): 897–9. PMID 2895828.
  12. ↑ Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonsky GA, Bernier RH (1991). "Mucosal immunity induced by enhance-potency inactivated and oral polio vaccines". J Infect Dis. 163 (1): 1–6. PMID 1845806.
  13. ↑ Modlin JF, Halsey NA, Thoms ML, Meschievitz CK, Patriarca PA (1997). "Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group". J Infect Dis. 175 Suppl 1: S228–34. PMID 9203721.
  14. ↑ Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.
  15. ↑ Cohen-Abbo A, Culley BS, Reed GW, Sannella EC, Mace RL, Robertson SE; et al. (1995). "Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval". Pediatr Infect Dis J. 14 (2): 100–6. PMID 7746690.
  16. ↑ Hardy GE, Hopkins CC, Linnemann CC, Hatch MH, Witte JJ, Chambers JC (1970). "Trivalent oral poliovirus vaccine: a comparison of two infant immunization schedules". Pediatrics. 45 (3): 444–8. PMID 5442915.
  17. ↑ Bass JW, Halstead SB, Fischer GW, Podgore JK, Wiebe RA (1978). "Oral polio vaccine. Effect of booster vaccination one to 14 years after primary series". JAMA. 239 (21): 2252–5. PMID 206735.
  18. ↑ Nishio O, Ishihara Y, Sakae K, Nonomura Y, Kuno A, Yasukawa S; et al. (1984). "The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years". J Biol Stand. 12 (1): 1–10. PMID 6699021.
  19. ↑ Ogra PL, Karzon DT, Righthand F, MacGillivray M (1968). "Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection". N Engl J Med. 279 (17): 893–900. doi:10.1056/NEJM196810242791701. PMID 20617594.
  20. ↑ Ogra PL (1984). "Mucosal immune response to poliovirus vaccines in childhood". Rev Infect Dis. 6 Suppl 2: S361–8. PMID 6740074.
  21. ↑ Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.
  22. ↑ Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.
  23. ↑ Cáceres VM, Sutter RW (2001). "Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication". Clin Infect Dis. 33 (4): 531–41. doi:10.1086/321905. PMID 11462191.
  24. ↑ el-Sayed N, el-Gamal Y, Abbassy AA, Seoud I, Salama M, Kandeel A; et al. (2008). "Monovalent type 1 oral poliovirus vaccine in newborns". N Engl J Med. 359 (16): 1655–65. doi:10.1056/NEJMoa0800390. PMID 18923170.

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Polio_prevention&oldid=1263367"